Results 161 to 170 of about 7,937 (220)

Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients. [PDF]

Sci Rep
Poledniczek M, Schmid LM, Kronberger C, Ermolaev N, Rettl R, Binder C, Camuz Ligios L, Eslami M, Nitsche C, Hengstenberg C, Badr Eslam R, Kammerlander A, Kastner J, Bergler-Klein Fesc J, Duca F.   +14 more
europepmc   +1 more source

Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy. [PDF]

Eur J Heart Fail
Krammer T, Baier MJ, Lutz V, Hübner AC, Zschiedrich T, Lukas D, Le Phu C, Wolf M, Maassen C, Wester M, Neef S, Schach C, Sag CM, Evert K, Paulus M, Meindl C, Tafelmeier M, Debl K, Maier LS, Wagner S, Röcken C, Mustroph J.   +21 more
europepmc   +1 more source

Characteristics and Prognosis of Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Diagnosed Before 65 Years Old. [PDF]

JACC Adv
Guijarro D, Eicher JC, Bézard M, Piriou N, Sauer F, Roubille F, Costa J, Réant P, Donal E, Bauer F, Bisson A, Bouchot O, Cariou E, Lairez O, Courand PY, Dagrenat C, Gueffet JP, Habib G, Jeanneteau J, Margerit L, Oghina S, Trésorier R, Kharoubi M, Damy T.   +23 more
europepmc   +1 more source

Real-World Clinical Evidence With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy　- A Contemporary Review. [PDF]

Circ Rep
Izumiya Y, Kuyama N, Hanatani S, Matsuzawa Y, Usuku H, Yamamoto E, Tsujita K.   +6 more
europepmc   +1 more source

Cardiac contractility modulation as a novel therapeutic approach in transthyretin amyloid cardiomyopathy to improve eligibility to stabilizer therapy: a case report. [PDF]

Eur Heart J Case Rep
Díaz Expósito A, Pérez Cabeza AI, Márquez Camas P, Robles Mezcua A, García Pinilla JM.   +4 more
europepmc   +1 more source

Transthyretin Amyloid Cardiomyopathy-2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. [PDF]

J Clin Med
Tschöpe C, Elsanhoury A, Kristen AV.
europepmc   +1 more source

A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary. [PDF]

Future Cardiol
Wixner J, Dispenzieri A, Amass L, Carlsson M, Riley S, Powers E, Kelly JW.   +6 more
europepmc   +1 more source

Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy. [PDF]

Cardiol Ther
Tian Z, Peng D, Ma W, Yan J, Wang J, Tang Y, Jin W, Liu Y, Jia C, Gao Y, Gong Y, Sun X, Chen N, Zhu S, Zhang S.   +14 more
europepmc   +1 more source

Advances in the assessment of cardiac amyloidosis [PDF]

, 2018
Földeák Dóra
core  

Influence of Age at Diagnosis on Clinical Disease Parameters in Wild-Type Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Asia
Kuyama N, Izumiya Y, Takashio S, Usuku H, Tabira A, Ishii M, Kidoh M, Oda S, Hanatani S, Matsuzawa Y, Yamamoto E, Hirai T, Ueda M, Tsujita K.   +13 more
europepmc   +1 more source